News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Panzem Gets Orphan Drug Status for Glioblastoma Multiforme

Posted on: 07/31/2006

Source: press release

Panzem Gets Orphan Drug Status for Glioblastoma Multiforme

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Entremed for their agent Panzem (2-methyoxyestradiol) for the treatment of glioblastoma multiforme (GBM).

The designation of orphan drug status was based on in vitro studies that demonstrated anti-proliferative activity against glioma cell lines, and anti-tumor activity in in vivo studies involving a preclinical model of glioblastoma.

Panzem has also previously been granted orphan drug status for multiple myeloma and ovarian cancer

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557